Effectiveness of BA.1-and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

被引：11

作者：

Arashiro, Takeshi ^{[1
,2
,3
,4
]}

Arima, Yuzo ^{[1
]}

Kuramochi, Jin ^{[5
,6
]}

Muraoka, Hirokazu ^{[7
]}

Sato, Akihiro ^{[8
]}

Chubachi, Kumi ^{[9
]}

Yanai, Atsushi ^{[10
]}

Arioka, Hiroko ^{[10
]}

Uehara, Yuki ^{[11
,12
]}

Ihara, Genei ^{[13
]}

Kato, Yasuyuki ^{[14
]}

Yanagisawa, Naoki ^{[15
]}

Ueda, Akihiro ^{[16
]}

Kato, Hideaki ^{[17
]}

Oka, Hideaki ^{[18
]}

Nishida, Yusuke ^{[18
]}

Nidaira, Yuki ^{[5
]}

Asami, Takahiro ^{[19
]}

Jinta, Torahiko ^{[20
]}

Nakamura, Akira ^{[21
]}

Oba, Kunihiro ^{[22
]}

Taniyama, Daisuke ^{[23
]}

Yamamoto, Kei ^{[18
]}

Tanaka, Katsushi ^{[17
]}

Ueshima, Kankuro ^{[24
]}

Fuwa, Tetsuji ^{[24
]}

Stucky, Ashley ^{[1
]}

Suzuki, Tadaki ^{[2
]}

Smith, Chris ^{[3
]}

Hibberd, Martin ^{[3
]}

Ariyoshi, Koya ^{[4
]}

Suzuki, Motoi ^{[1
]}

机构：

[1] Natl Inst Infect Dis, Ctr Surveillance Immunizat & Epidemiol Res, Tokyo, Japan

[2] Natl Inst Infect Dis, Dept Pathol, Tokyo, Japan

[3] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England

[4] Nagasaki Univ, Sch Trop Med & Global Hlth, Nagasaki, Japan

[5] Kuramochi Clin Interpk, Tochigi, Japan

[6] Tokyo Med & Dent Univ, Dept Global Hlth Promot, Tokyo, Japan

[7] Clin TAMACHI, Tokyo, Japan

[8] KARADA Internal Med Clin, Tokyo, Japan

[9] Chubachi Internal Resp Med Clin, Tokyo, Japan

[10] St Lukes Int Hosp, Dept Gen Internal Med, Tokyo, Japan

[11] St Lukes Int Hosp, Dept Clin Lab, Tokyo, Japan

[12] Fujita Hlth Univ, Sch Med, Dept Infect Dis, Aichi, Japan

[13] Machida Ekimae Naika Clin, Tokyo, Japan

[14] Int Univ Hlth, Welf Narita Hosp, Dept Infect Dis, Chiba, Japan

[15] Yanagisawa Clin, Tokyo, Japan

[16] Japanese Red Cross Med Ctr, Dept Infect Dis, Tokyo, Japan

[17] Yokohama City Univ Med, Infect Prevent & Control Dept, Yokohama, Japan

[18] Saitama Med Ctr, Dept Gen Internal Med & Infect Dis, Saitama, Japan

[19] Sano Kosei Gen Hosp, Dept Internal Med, Tochigi, Japan

[20] St Lukes Int Hosp, Dept Pulm Med, Tokyo, Japan

[21] Asahi Gen Hosp, Dept Internal Med, Chiba, Japan

[22] Showa Gen Hosp, Dept Pediat, Tokyo, Japan

[23] Showa Gen Hosp, Dept Infect Dis, Tokyo, Japan

[24] NATURALI Co Ltd, Tokyo, Japan

来源：

OPEN FORUM INFECTIOUS DISEASES | 2023年 / 10卷 / 06期

关键词：

COVID-19; SARS-CoV-2; variants; test-negative design; vaccine effectiveness;

D O I：

10.1093/ofid/ofad240

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined). In this multi-center study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent vaccines against symptomatic infection during the BA.5-dominant period was high compared to no vaccination (65%/76%) and moderate compared to monovalent vaccines >6 months before (46% combined).

引用

页数：6

共 50 条

[1] Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages
Ackerson, Bradley K.
Bruxvoort, Katia J.
Qian, Lei
Sy, Lina S.
Qiu, Sijia
Tubert, Julia E.
Lee, Gina S.
Ku, Jennifer H.
Florea, Ana
Luo, Yi
Bathala, Radha
Stern, Julie
Choi, Soon K.
Takhar, Harpreet S.
Aragones, Michael
Marks, Morgan A.
Anderson, Evan J.
Zhou, Cindy Ke
Sun, Tianyu
Talarico, Carla A.
Tseng, Hung Fu
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
[2] Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan
Arashiro, Takeshi
Arima, Yuzo
Kuramochi, Jin
Muraoka, Hirokazu
Sato, Akihiro
Chubachi, Kumi
Oba, Kunihiro
Yanai, Atsushi
Arioka, Hiroko
Uehara, Yuki
Ihara, Genei
Kato, Yasuyuki
Yanagisawa, Naoki
Nagura, Yoshito
Yanai, Hideki
Ueda, Akihiro
Numata, Akira
Kato, Hideaki
Oka, Hideaki
Nishida, Yusuke
Ishii, Koji
Ooki, Takao
Nidaira, Yuki
Asami, Takahiro
Jinta, Torahiko
Nakamura, Akira
Taniyama, Daisuke
Yamamoto, Kei
Tanaka, Katsushi
Ueshima, Kankuro
Fuwa, Tetsuji
Stucky, Ashley
Suzuki, Tadaki
Smith, Chris
Hibberd, Martin
Ariyoshi, Koya
Suzuki, Motoi
VACCINE, 2023, 41 (47) : 6969 - 6979
[3] Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
Kopel, Hagit
Nguyen, Van Hung
Boileau, Catherine
Bogdanov, Alina
Winer, Isabelle
Ducruet, Thierry
Zeng, Ni
Bonafede, Mac
Esposito, Daina B.
Martin, David
Rosen, Andrew
van de Velde, Nicolas
Vermund, Sten H.
Gravenstein, Stefan
Mansi, James A.
VACCINES, 2023, 11 (11)
[4] Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
Maeda, Haruka
Saito, Nobuo
Igarashi, Ataru
Ishida, Masayuki
Terada, Mayumi
Ito, Takayasu
Ikeda, Hideko
Kamura, Hiroshi
Motohashi, Iori
Kimura, Yuya
Komino, Masaru
Arai, Hiromi
Kuwamitsu, Osamu
Akuzawa, Nobuhiro
Sando, Eiichiro
Morikawa, Toru
Imura, Haruki
Inoue, Hiroki
Hayakawa, Tomoichiro
Teshigahara, Osamu
Ohara, Yasuji
Suzuki, Motoi
Morimoto, Konosuke
EXPERT REVIEW OF VACCINES, 2023, 22 (01) : 288 - 298
[5] SARS-CoV-2 Omicron (BA.4, BA.5) variant: Lessons learned from a new variant during the COVID-19 pandemic
Erabi, Gisou
Faridzadeh, Arezoo
Parvin, Ali
Deravi, Niloofar
Rahmanian, Mohammad
Fathi, Mobina
Aleebrahim-Dehkordi, Elahe
Rezaei, Nima
HEALTH SCIENCE REPORTS, 2024, 7 (02)
[6] Protection against SARS-CoV-2 BA.4 and BA.5 subvariants via vaccination and natural infection: A modeling study
Okada, Yuta
Kayano, Taishi
Anzai, Asami
Zhang, Tong
Nishiura, Hiroshi
MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2023, 20 (02) : 2530 - 2543
[7] Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death
Huang, Zhuoying
Xu, Shuangfei
Liu, Jiechen
Wu, Linlin
Qiu, Jing
Wang, Nan
Ren, Jia
Li, Zhi
Guo, Xiang
Tao, Fangfang
Chen, Jian
Lu, Donglei
Sun, Xiaodong
Wang, Weibing
BMC MEDICINE, 2022, 20 (01)
[8] Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death
Zhuoying Huang
Shuangfei Xu
Jiechen Liu
Linlin Wu
Jing Qiu
Nan Wang
Jia Ren
Zhi Li
Xiang Guo
Fangfang Tao
Jian Chen
Donglei Lu
Xiaodong Sun
Weibing Wang
BMC Medicine, 20
[9] Effectiveness of Adapted COVID-19 Vaccines and Ability to Establish Herd Immunity against Omicron BA.1 and BA4-5 Variants of SARS-CoV-2
Plans-Rubio, Pedro
VACCINES, 2023, 11 (12)
[10] Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5
Torres, Carolina
Nabaes Jodar, Mercedes
Acuna, Dolores
Zambrana Montano, Romina Micaela
Alberto Culasso, Andres Carlos
Fernando Amadio, Ariel
Aulicino, Paula
Ceballos, Santiago
Cacciabue, Marco
Debat, Humberto
Dus Santos, Maria Jose
Florencia Eberhardt, Maria
Espul, Carlos
Fay, Fabian
Ailen Fernandez, Maria
Fernandez, Franco
Fernandez Munoz, Juan Manuel
Ferrini, Florencia
Gallego, Fernando
Angelica Giri, Adriana
Cerri, Agustina
Bolatti, Elisa
Ines Gismondi, Maria
Goya, Stephanie
Gramundi, Ivan
Matias Irazoqui, Jose
Alberto Konig, Guido
Leiva, Viviana
Lucero, Horacio
Marquez, Nathalie
Nardi, Cristina
Ortiz, Belen
Pianciola, Luis
Beatriz Pintos, Carolina
Fabiana Puebla, Andrea
Victoria Rastellini, Carolina
Ezequiel Rojas, Alejandro
Sfalcin, Javier
Suarez, Ariel
Tittarelli, Estefania
Toro, Rosana
Vanina Villanova, Gabriela
Cecilia Ziehm, Maria
Carla Zimmermann, Maria
Zunino, Sebastian
Valinotto, Laura
Viegas, Mariana
VIRUSES-BASEL, 2023, 15 (02):

← 1 2 3 4 5 →